Phragmites rhizoma polysaccharide-based nanocarriers for synergistic treatment of ulcerative colitis

Int J Biol Macromol. 2022 Nov 1:220:22-32. doi: 10.1016/j.ijbiomac.2022.07.245. Epub 2022 Aug 4.

Abstract

The purpose of this study was to construct Phragmites rhizoma polysaccharide-based nano-drug delivery systems (PRP2-SeNPs-H/Aza-Lips) for synergistically alleviating ulcerative colitis and to investigate the important roles of Phragmites rhizoma polysaccharide-based nanocarriers in PRP2-SeNPs-H/Aza-Lips. Phragmites rhizoma polysaccharide (PRP2) was isolated and used for the preparation of Phragmites rhizoma polysaccharide selenium nanoparticles with low selenium content (PRP2-SeNPs-L) and high selenium content (PRP2-SeNPs-H). Based on the electrostatic attraction between PRP2-SeNPs-H and azathioprine liposomes (Aza-Lips), PRP2-SeNPs-H/Aza-Lips were constructed for precise delivery of the model drug azathioprine (Aza) to colon lesions. Results showed that PRP2 significantly alleviated the clinical symptoms and colon tissue damage and down-regulated the levels of inflammatory factors in serum and colon, demonstrating beneficial effects on mice with ulcerative colitis. PRP2-SeNPs-L had better relieving effects on ulcerative colitis. Phragmites rhizoma polysaccharide-based nanocarriers may protect azathioprine liposomes against gastrointestinal digestion, enhance the therapeutic effects on ulcerative colitis, and significantly reduce liver damage from azathioprine, which helps to improve the efficacy and toxicity of clinical drugs.

Keywords: Nanodrug delivery system; Polysaccharide; Ulcerative colitis.

MeSH terms

  • Animals
  • Azathioprine / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / pathology
  • Liposomes / therapeutic use
  • Mice
  • Nanoparticles*
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Selenium* / therapeutic use

Substances

  • Liposomes
  • Polysaccharides
  • Selenium
  • Azathioprine